SLC35G1: A Potential Drug Target for Pain, Anxiety and Memory

Target Name: SLC35G1

NCBI ID: G159371

SLC35G1

SLC35G1: A Potential Drug Target for Pain, Anxiety and Memory

SLC35G1 (S35G1_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and pancreas. It is a member of the sodium channel subfamily 3 (SLC3) and is responsible for transmitting electrical signals through sodium channels in the plasma membrane of cells.

SLC35G1 has been identified as a potential drug target due to its involvement in various physiological processes in the body. For example, it has been shown to be involved in the regulation of pain perception, anxiety and depression, and memory. Additionally, SLC35G1 has been linked to the development of certain neurological disorders, such as epilepsy and Alzheimer's disease.

One of the key advantages of SLC35G1 as a drug target is its high expression across different tissues and cells. This makes it a promising candidate for targeting with small molecules, antibodies, or other therapeutic agents.

SLC35G1 is also known as S35G1, which is a gene that encodes a protein with a molecular weight of approximately 110 kDa. The protein is composed of four known isoforms, which are different in their localization and expression patterns. SLC35G1 is predominantly expressed in the brain , heart, and liver, and is also found in various other tissues of the body, such as the pancreas and salivary glands.

SLC35G1 is involved in the regulation of a wide range of physiological processes in the body. One of its most well-known functions is its role in the regulation of pain perception. SLC35G1 has been shown to be involved in the transmission of pain signals from the brain to the spinal cord, and has been linked to the development of chronic pain conditions.

In addition to its role in pain perception, SLC35G1 is also involved in the regulation of anxiety and depression. Studies have shown that SLC35G1 is positively correlated with symptoms of anxiety and depression, and that its levels are decreased in individuals with these conditions. This suggests that SLC35G1 may play a role in the development and treatment of these conditions.

SLC35G1 is also thought to be involved in the regulation of memory and learning. Studies have shown that SLC35G1 is expressed in the brain and that it is involved in the transfer of information from short-term memory to long-term memory. This suggests that SLC35G1 may be a promising target for the development of memory-related drugs.

In conclusion, SLC35G1 is a protein that is expressed in various tissues of the human body and is involved in the regulation of a wide range of physiological processes in the body. As a potential drug target, SLC35G1 is due to its high expression and involvement in various physiological processes, including pain perception, anxiety and depression, and memory. Further research is needed to fully understand the role of SLC35G1 in the regulation of these processes and to develop effective treatments for these conditions.

Protein Name: Solute Carrier Family 35 Member G1

Functions: May play a role in intracellular calcium sensing and homeostasis. May act as a negative regulator of plasma membrane calcium-transporting ATPases preventing calcium efflux from the cell

The "SLC35G1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35G1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets